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Amphotericin B is a broad spectrum antifungal agent used to treat fungal infections. Organogel 
is a semisolid preparation in which the apolar phase gets immobilized within spaces of the three-
dimensional structure. The current study aimed at the formulation and comparative evaluation of 
sorbitan monostearate organogels and pluronic lecithin organogels (PLO). Different compositions 
of span 60 based organogels were prepared by varying the concentrations of the span 60 and PLO 
gels were prepared by varying the concentration of Pluronic F 127. The developed organogels were 
subjected to various characteristics such as pH, viscosity, spreadability, extrudability, and drug 
release studies. The optimized formulations were evaluated against Candida albicans and carried out 
ex vivo release study. The optimized formulation was selected from span 60 based organogels, and 
pluronic lecithin organogels were S1 and P1, respectively. The optimized formulation (S1) showed 
effective inhibition against Candida albicans. The skin irritation test was carried out on albino mice 
for optimized formulations and results showed that no irritation to the skin. Based on the results, 
organogels prepared by sorbitan monostearate showed better antifungal activity, and also all the 
formulations were found to be stable and safe throughout the study period.
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INTRODUCTION
For many decades, topical drug delivery system is 
considered as the best and easiest way of administration of 
therapeutic agents for local effect; however, it also shows 
some systemic effects. Absorption of the drug through 
topical application is easy because of the presence of 
innumerable blood vessels in the skin. Amongst various 
topical formulations, the semisolid system holds keen 
importance due to its ease of absorption through the skin 
layers. Topical dosage forms are more effective and less 
toxic than conventional dosage forms. There are different 
factors which can affect the topical absorption of drugs 
such as particle size of the drug, chemical nature of the 
drug, physiological factors such as moisture of the skin, 
skin texture, skin temperature, age, sex, and disease 
conditions etc. (Quindós, 2014). Numerous novel topical 
formulations have evolved in the last decades (Nakhat et 
al., 2005). Gels are the convenient form of topical delivery 
system which has a lot of application in the pharmaceutical 
industry. Compared to other topical semisolid preparations 
like ointment and cream, the gel has got better application 
property and stability. It is also providing controlled drug 
delivery. Nowadays, several novel gels are available in the 
market. Among which organogel, which is a new type of 
gel system became popular in a short time because of its 
various advantages. The popularity of organogel increases 
because of its penetration power through the skin layers 
without the addition of chemical enhancer, ease of 
preparation, and it can accommodate both hydrophilic 
and lipophilic therapeutic agents (Voltan, Fusco-Almeida, 
Mendes-Giannini, 2014). 
Cutaneous fungal infection is one of the most 
common diseases in all over the world. Many fungi 
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which are occurring in our environment can cause 
various types of infections in different parts of 
the body in both humans and animals. There are 
several drugs available to treat these types of fungal 
infections such as ketoconazole, clotrimazole, and 
miconazole etc. Amphotericin B is one of the broad 
spectrum antifungal agent which is usually used 
to treat systemic fungal infection by intravenous 
administration. Topical application of amphotericin 
B is limited because of its low absorption through 
mucosa or skin. Due to its lipophilic nature, it does 
not dissolve in an aqueous medium. 
Various topical formulations are available such 
as cream, gel, lotion, but these are undesirable for 
many drugs due to its poor absorption and other side 
effects. To avoid all these drawbacks, it is a new idea to 
prepare a formulation of organogel incorporating with 
amphotericin B as the therapeutic agent. Organogel 
has better penetration power through the skin layers 
without any chemical catalyst, and it is a good carrier 
for lipophilic drugs. These novel drug delivery systems 
can also produce controlled drug delivery; it can also 
significantly improve its performance in terms of 
efficacy, safety and stability (Xie et al., 2014).
MATERIAL AND METHODS
Amphotericin B was received as a gift sample 
from Cipla Pvt. Ltd. Mumbai, India. Pluronic F127 
was procured from Sigma Aldrich, USA. Soya lecithin, 
isopropyl myristate, isopropyl palmitate, and sorbic acid 
were obtained from Hi-Media laboratories, Mumbai, 
India. All the materials used in this study are of 
analytical grades.
METHOD OF PREPARATION OF ORGANOGEL
For the preparation of organogels two different 
organogelators were selected, like sorbitan monostearate 
based organogel and lecithin based organogel.
Preparation of sorbitan monostearate organogel
Sorbitan monostearate (span 60) based organogels 
were prepared by a simple method, in which required the 
amount of span 60 was dissolved into isopropyl myristate 
(10% w/v) in a beaker and 2% w/v of polysorbate was 
added to the above solution. This mixture was heated to 
60°C in a water bath, and a homogenous solution was 
obtained. In another beaker, 0.1% w/w of amphotericin 
B was dissolved in 5 mL of dimethyl sulfoxide (DMSO), 
and this was added to the homogenous solution with 
continuous stirring at room temperature (Chen, Playford, 
Sorrell, 2010). The solution was further cooled, and a 
semisolid gel was obtained. Six different formulations 
were prepared by changing the concentration of span 
60 (Chandrasekar, 2011). The compositions of different 
formulations were summarized in Table I.











S1 0.1 18 2 2 100
S2 0.1 20 2 2 100
S3 0.1 22 2 2 100
S4 0.1 24 2 2 100
S5 0.1 26 2 2 100
S6 0.1 28 2 2 100
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Preparation of pluronic-lecithin 
organogel (lecithin based)
Pluronic lecithin orange consists of aqueous phase 
as well as the oil phase. The aqueous phase was prepared 
by dissolving the required amount of Pluronic F127 in 
cold water with continuous stirring, and this dispersion 
was stored in a freezer for 24 h to obtain a clear polymer 
solution. Potassium sorbate was added as a preservative 
(Jose, Charyulu, 2016). Similarly, the oil phase was 
prepared by dissolving the specified quantity of soya 
lecithin in isopropyl palmitate with continuous stirring. 
Sorbic acid was added as a preservative. This solution was 
kept at room temperature for 24 h. Finally, the organogel 
was prepared by mixing of oil phase with the aqueous 
phase. Amphotericin B (0.1%w/w) was dissolved in a 
minimum quantity of DMSO and added to the oil phase. 
The oil phase containing the drug was added in drop wise 
manner to the aqueous phase with continuous stirring 
(Petrikkos, Skiada, 2007). The formulae for preparation 
of pluronic lecithin organogel are given in Table II.
Physicochemical Characterization of Organogel
Compatibility studies
The FTIR spectra of the pure drug (amphotericin 
B), pluronic F127, span 60 and the formulations were 
recorded on an FTIR spectrometer (Shimadzu FTIR 
8300 Spectrophotometer). The signals arising out 
of various intramolecular stretching and bending 
vibrations have been expressed in wave numbers. The 
spectra obtained for drug, physical mixture and the final 
formulation was compared.
Physical appearance
The prepared organogel was visually inspected for 
its colour, homogeneity, and consistency.
Measurement of pH
The pH of all the formulations was determined by 
placing the electrode of electronic pH meter in contact 
with the surface of the prepared gel and allowing 
equilibrating for 1 min (Singh, Pramanik, Pal, 2015).
Gel-sol transition temperature
The gel-sol transition temperature of all gels 
was determined by incubating the organogels in a 
temperature bath at a temperature ranging from 25 ºC 
– 60 ºC. The temperature of the water bath increased by 
5°C every 5 min. The temperature was noted at which 
the gel started to flow when the beaker was inverted 
(Mohamed, 2004).
TABLE II - Formulation of pluronic lecithin organogel from P1 to P6
Components Content
Formulation code
P1 P2 P3 P4 P5 P6
Drug(% w/v) Amphotericin B 0.1 0.1 0.1 0.1 0.1 0.1
Oil phase
(% w/v)
Soya lecithin 10 10 10 10 10 10
Potassium sorbate 0.4 0.4 0.4 0.4 0.4 0.4
Isopropyl palmitate up to 100 100 100 100 100 100
Aqueous phase (%w/v)
Pluronic F 127 30 34 38 42 46 50
Sorbic acid 0.4 0.4 0.4 0.4 0.4 0.4
Distilled water up to 100 100 100 100 100 100
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Viscosity
The viscosity of all the organogel was determined 
by using Brookfield viscometer (Brookfield DV-II+ 
Pro). The samples were taken in a beaker and viscosity 
was measured using spindle no: 96 at room temperature 
and increase in angular velocity 5 rpm to 100 rpm and 
constructed rheogram(Gendy, Jun, Kassem, 2002).
Spreadability
All the prepared formulations were evaluated for 
the spreadability by using two glass plates. A circle of 1 
cm diameter was marked in one of the glass plates, and 
0.5 g of the formulation was placed on it. The second 
glass plate placed over the first glass plate, and 1kg of 
weight was kept over it for 5 min. Spreadability of the 
gel was measured by increased diameter after 5 min 
(Shivhar, Jain, Mathur, 2009).
Extrudability test
Extrudability test of all the prepared formulations 
was done by using Monsanto hardness tester. About 15 g 
of the prepared formulation was placed in the aluminium 
tube, and the plunger of the tester was adjusted to hold 
the tube properly. About 1 kg/cm2 pressure was applied 
to it for 30 sec. The amount of formulation extruded out 
was weighed, and the procedure was repeated at three 
equidistance places of the tube (Hosadurga et al., 2014).
Drug content determination
The amphotericin B showed maximum absorbance 
in the UV region at its characteristic wavelength 
(409 nm). A calibration curve was constructed at 
different amphotericin B concentrations. Since other 
ingredients in the formulation give no absorbance at 
409 nm, the absorbance obtained from the formulation 
would be exclusively from amphotericin B. The limits 
of detection (LOD), and the limits of quantification 
(LOQ) were found to be 0.24 and 0.72 µg/mL 
respectively. From each formulation, weigh accurately 
1 g of formulation and dissolved in 2 mL DMSO in a 
100 mL volumetric flask. The volume was made up 
to the mark with phosphate buffer of pH 7.4. Again 
1 mL from this stock solution was taken and diluted 
to 100 mL with the same buffer, and the absorbance 
was measured at 409 nm by using UV/Visible 
spectrometer. This absorbance was correlated with the 
calibration curve, and drug content was determined 
(Shaikh et al., 2009).
In vitro drug release 
In vitro, drug release studies were carried out in 
modified in vitro permeation apparatus using dialysis 
membrane (MWCO 1000 Daltons). The phosphate 
buffer of pH 7.4 was used as the dissolution medium. 
The dialysis membrane was soaked in the dissolution 
medium for overnight. Accurately weighed 1 g of 
organogel and placed in the centre of the dialysis 
membrane and tied to one of the opening ends of the 
specially designed glass cylinder (glass cylinder with an 
opening at both ends and a diameter of 3.4 cm called as 
donor chamber). The glass cylinder was attached to the 
metallic shaft and dipped in a beaker containing 50 mL 
of phosphate buffer of pH 7.4, and it is placed in such 
a way that the dialysis membrane just touched to the 
receptor dissolution medium surface. The dissolution 
medium was kept at a temperature of 37+ 0.5 ºC and 
stirred throughout the studies at 50 rpm. In a specified 
time interval, aliquots of 3 mL sample from the receptor 
medium were withdrawn, and the same volume was 
replaced with phosphate buffer of pH 7.4 to maintain 
perfect sink conditions. The absorbance of the samples 
was measured by UV spectrometer at 409 nm after 
suitable dilution (Khan et al., 2013).
Screening of antifungal activity of the 
formulation against Candida albicans
The antifungal activity studies of the optimized 
formulations were carried out by the cup plate method 
(Hammer, Carson, Riley,1999). The organism used 
for the study was Candida albicans ATCC-14053. The 
optimized formulations (S1 and P1) were taken for the 
antifungal activity study. The DMSO was used as the 
control. Pure Amphotericin B was used as a reference 
standard, and it was dissolved in a minimum volume 
of DMSO. The culture medium was prepared by 
dissolving 6.5 g of sabouraud dextrose agar in 100 mL 
distilled water by heating and sterilized by autoclaving 
at 15 lbs/sq inch pressure for 15 min. After that, the 
medium was poured into three Petri plates and kept 
in an incubator at 37±2 ºC. A loopful of the organism 
was transferred from the mother culture to the 
sterilized sabouraud dextrose agar medium by spread 
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plate method. The Petri plates were marked into four 
equal parts. The first part was marked as S (standard), 
the second part was marked as T (test), the third part 
was marked as S6 (formulation), and the fourth part 
was marked as P1 (formulation). The cup or holes 
about 8mm in diameter were cut into the centre of 
each part of the medium with a sterile cork borer. 
The hole S (standard) was filled with the solution of 
0.01mg amphotericin B in DMSO and T (test) was 
filled with placebo gel. The optimized formulations 
S6 and P1 were weighed equivalent to 0.01mg of drug 
and placed in the holes S1 and P1 respectively. The 
plates were transferred into biological oxygen demand 
incubator and maintained at 37±2 ºC for 24-48 h. 
After incubation, the Petri plates were observed for 
the zone of inhibition. The diameter of the zone of 
inhibition was reported in mm (EI Maghraby, Barry, 
William,2008).
Ex-vivo permeation studies 
The modified validated ex-vivo permeation 
apparatus was used for the ex-vivo drug release studies 
through pig skin. The medium used in this study was 
a phosphate buffer of pH 7.4. The pig ear skin was 
collected from the local slaughter house and cleaned 
it properly. The collected skin with suitable size was 
stored at -20 ºC. Before the study, the pig ear skin was 
taken out of the freezer and allowed to come into room 
temperature. Weighed accurately 1g of the organogel 
and placed in the centre of the pig ear skin and tied to 
the specially designed glass cylinder, which was donor 
compartment (Schwartz et al., 2014). The glass cylinder 
was then attached to the metallic shaft and suspended 
in 50 mL dissolution medium so that the membrane 
just touched to the receptor surface. The temperature of 
the dissolution medium was maintained at 37+ 0.5 ºC 
throughout the experiment, and the medium was stirred 
at 50 rpm using a magnetic stirrer. In specified intervals, 
3 mL sample was taken from the receptor medium, and 
the same volume was replaced with phosphate buffer 
of pH 7.4. The filtered samples were analyzed by UV 
spectrometer at 409 nm after suitable dilution (Tazrart 
et al., 2017). 
Skin irritation test
After the approval from the CPCSEA (Committee 
for the Purpose of Control and Supervision of 
Experiments on Animals), skin irritation test was 
carried out for optimized formulations on Albino mice. 
For the studies, eight mice of either sex were selected. 
The selected mice were caged together and provided 
with normal food. The mice were anaesthetized using 
anaesthetic ether. Hairs were depleted from the back of 
mice by depilatories, and an area of 2 cm2 was marked. 
After 24 h of depilation, the mice were subjected to 
irritation studies. The animals were categorized into 
four sets; each set contains two animals in which, and 
one was used as control, and the other one was used 
as a test. On the control, 100 mg of gel without drug 
was applied, and on the test, 100 mg of the optimized 
formulation was applied. The skin surface was observed 
for any visible change such as erythema (redness) after 
24, and 48 h of the formulation application. The mean 
erythemal scores were recorded depending on the 
degree of erythema: no erythema = 0, slight erythema 
(barely perceptible-light pink) = 0.5, moderate erythema 
(dark pink) = 1 (Nava et al., 2011). 
Stability studies
The accelerated stability studies for the optimized 
formulation were carried out as per the ICH guidelines 
(Nakhat et al., 2005). The optimized gels were filled in 
a collapsible tube and stored away from light at 25± two 
ºC and 40±2 ºC and 75% relative humidity (RH) for 
three months. After storage, the samples were tested for 
their visual appearance, pH, % drug content and % drug 
release (Bhalodia, Shukla, 2011).
RESULTS AND DISCUSSION
Compatibility studies
FTIR spectrum of amphotericin B showed a 
characteristic sharp peak at 3413.15 cm-1 due to the 
amine group, peak at 2923.22 cm-1 representing hydroxyl 
group and C-O stretching peak at 1181 cm-1. When 
compared with the pure drug, no considerable change 
in the IR peaks of the drug was observed in spectra of 
optimized formulations; it indicates the absence of any 
incompatibility between drug and excipients.
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FIGURE 1 - FTIR spectrum of amphotericin B.
FIGURE 2 - FTIR spectrum of span 60.
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FIGURE 3 - FTIR spectrum of optimized formulation S1.
FIGURE 4 - FTIR spectrum of pluronic F127.
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FIGURE 5 - FTIR spectrum of optimized formulation P1.
Physical appearance
All the developed organogel was creamy 
light yellowish, non-transparent and showed good 
homogeneity. The span 60 based organogels was 
appeared to be little more yellowish than the pluronic 
lecithin organogel. The results were depicted in Table III.
The pH of all the formulations was measured and 
enlisted in Table III. The pH of all the formulations was 
remained within the normal skin pH range, indicated 
that it would not cause any irritation upon administration 
(Essa, 2010).
Gel-sol transition temperature
The gel-sol transition temperature of all the 
formulations was found to be in the range of 42 °C-
50 °C as enlisted in Table III. In the case, both types 
of organogels the gel-sol transition directly depends 
on the viscosity of the system. The gel-sol transition 
temperature of all the pluronic lecithin organogels 
was found to be more than that of the span 60 based 
organogel.
Viscosity, Spreadability and Extrudability
The viscosity of all the prepared formulation 
was determined by Brookfield viscometer, and the 
data were shown in Figure 6 and 7. The viscosity of 
the span 60 based organogel was increased gradually 
from the formulation S1 to S6 due to the increased 
concentration of span 60. In the case of pluronic 
lecithin organogel, formulation P6 showed the highest 
viscosity and P1 showed the least viscosity indicated 
that the direct effect of polymer concentration on 
viscosity. However, viscosities of all the pluronic 
lecithin organogel were found to be more than that 
of the span 60 based organogel. The rheogram was 
constructed for all the organogel formulations and it was 
found that all the formulation exhibits shear thinning 
property (Essa, 2010). The values of the spreadability 
(Table IV) of the formulated organogel showed that 
only a small amount of force is required to spread 
the gel easily. The entire span 60 based organogels 
showed better spreadability when compared to 
pluronic lecithin organogel (Gupta, Nappinnai, Gupta, 
2010). Extrudability of all the formulations were 
determined and listed in Table IV. The results implied 
that more than 90% of the contents were extrudable 
indicating they have excellent extrudability. (>90% 
extrudability: excellent, >80% extrudability: good, 
>70% extrudability: fair). The extrudability studies 
indicated that suitable consistency of the gel was 
required to extrude the gel from the tube uniformly. 
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FIGURE 6 - Rheogram of span 60 based organogel.
TABLE III - Physical appearance, pH and gel-sol transition temperature
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FIGURE 7 - Rheogram of pluronic lecithin organogel.
Drug content
The drug content of developed gels was found 
to be in the range of 96-99% (Table IV). There was 
no significant difference in the drug content among 
the organogels, indicated the drug was uniformity 
distributed in the gel base. 
TABLE IV - Spreadability, extrudability, drug content
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In vitro drug release studies
In vitro drug release profile of all the formulated 
span 60 based organogel was given in Figure 8. The 
study was carried out for eight h using modified in vitro 
permeation apparatus through the dialysis membrane. 
All the formulations showed extended drug release for 
eight h. However, S1 showed the highest drug release 
of 99.4% at the end of 8 h. The order of drug release 
from the formulation S1 to S6 varied as follows, 
S1>S2>S3>S4>S5>S6. Among the formulations from 
S1 to S6, as the concentration of span 60 increased, 
the drug release was decreased. The decrease in drug 
release was due to an increase in alkyl chain length of 
surfactant. The formulation S1 was selected as the best 
due to its highest drug release within eight h (Tavano 
et al., 2010).
In vitro drug release profile of pluronic-lecithin 
organogel was also carried, and results were shown 
in Figure 9. The drug release from all the developed 
gel was extended to 12 h. The order of drug release 
from the formulation P1 to P6 varied as follows, 
P1>P2>P3>P4>P5>P6. The drug release values from 
P1 to P6 indicated that, as the polymer concentration 
increased, the drug release was decreased, which 
might be due to extensive formation of network-like 
structures with very high viscosity. The formulation 
P1 was selected as the best due to its effective 
prolonged release of the drug throughout 12 h (Srinivas 
et al., 2010).
FIGURE 8 - Drug release profile of span 60 based organogel in phosphate buffer of pH 7.4 as a function of hours.
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FIGURE 9 - Drug release profile of pluronic lecithin organogel in phosphate buffer of pH 7.4 as a function of hours.
Kinetic studies
In the case of span 60 based organogel, the release 
kinetics best-fit model indicated that formulations S1 
to S4 followed the Higuchi model while S5 and S6 
followed first order release. The optimized formulation 
S1 followed the Higuchi model with the R2 value of 
0.993 (as shown in Table V). 
In the case of pluronic lecithin organogel, the release 
kinetics best-fit model indicated that formulations P1 to 
P4 followed Korsmeyer-Peppas model and P5 and P6 
followed zero order release. The results were shown in 
Table VI. The optimized formulation P1 best fit to the 
Korsmeyer Peppas model with R2 value of 0.990. The 
values of release exponent “n” obtained by applying the 
Peppas equation was found to be less than 0.45, which 
revealed that the drug release follows Fickian diffusion 
(Ning et al., 2005). 
In vitro antifungal activity against Candida albicans
The in the vitro antifungal study was carried out 
by cup plate method to compare the effectiveness of 
the optimized formulations to controls against Candida 
albicans and results were given in Figure 10. The zone 
of inhibition produced by the optimized formulations 
S1 and P1 were compared with the zone of inhibition 
produced by the standard pure drug. The formulation of 
S1 and P1 showed a zone of inhibition of 14.21±0.002 mm 
and 10.11±0.005 mm, respectively. So the formulation 
S1 had comparatively higher antifungal activity than 
formulations P1. 
FIGURE 10 - Comparison of antifungal activity of formulation 
S1 and P1 against Candida albicans by cup plate method.
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TABLE V - Kinetic models of formulations S1 to S6
Formulation code
Kinetic models
Zero order First order Higuchi Korsmeyer-peppas
R2 k R2 k R2 k R2 k n
S1 0.960 -0.191 0.985 -0.0017 0.993 4.289 0.955 0.691 0.343
S2 0.961 -0.188 0.986 -0.0016 0.99 4.19 0.958 0.689 0.191
S3 0.971 -0186 0.985 -0.0015 0.986 4.13 0.963 0.687 0.174
S4 0.975 -0.184 0.986 -0.0014 0.982 4.06 0.968 0.686 0.157
S5 0.980 -0.178 0.983 -0.0013 0.978 3.94 0.973 0.684 0.142
S6 0.983 -0.177 0.980 -0.0013 0.972 3.88 0.977 0.683 0.125
TABLE VI - Kinetic models of formulations P1 to P6
Formulation code
Kinetic models
Zero order First order Higuchi Korsmeyer-peppas
R2 K R2 k R2 k R2 k n
P1 0.978 -0.130 0.969 -0.0009 0.967 3.06 0.990 0.6615 0.051
P2 0.982 -0.122 0.984 -0.0008 0.969 2.88 0.995 0.6551 0.030
P3 0.989 -0.121 0.992 -0.0007 0.962 2.84 0.997 0.6576 -0.005
P4 0.993 -0.115 0.994 -0.0006 0.950 2.68 0.994 0.6544 -0.046
P5 0.993 -0.105 0.992 -0.0006 0.951 2.46 0.987 0.6453 -0.070
P6 0.996 -0.101 0.995 -0.0006 0.951 2.34 0.977 0.6448 -0.102
Ex vivo drug release studies
The ex vivo drug release studies of the optimized 
formulations (S1 and P1) were carried out using a modified 
ex vivo permeation apparatus through the pig membrane, 
and the results were given in figure 11. The release of the 
drug from the formulation S1 through pig membrane was 
found to be 99.3%, but the formulation P1 showed only 
88.2%. The ex vivo drug release profile showed a better 
release of formulation S1 when compared to P1. The 
formulation S1 showed maximum drug release within ten 
h. The probable reason could be the stronger interaction 
between S1 formulation and lipids in the pig membrane, 
causing their rearrangement and thus facilitated drug 
penetration. This result was in agreement with the previous 
data reported by Staub (Staub, Schapoval, Bergold, 2005). 
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FIGURE 11 - Ex vivo drug release profile of formulation S1 and P1 through pig membrane.
Skin irritation studies
The result obtained from the skin irritation study 
was given in Table VII. The optimized formulations 
were applied to the skin of mice as per the procedure 
is given in methodology (Figure 12(a)) and observed 
for sensitivity reaction up to 48 h. There was no sign 
of development of erythema at the end of 24 h after 
application of formulations (Figure 12(b)). From the set 2 
and set 5 animals, the test a animal showed slight, patchy 
erythema and graded as 0.5 at the end of 48 h (Figure 
12(c)). The results obtained were graded according to 
the standard grading system, and the average primary 
irritation was calculated. The primary irritation index 
on each mouse was calculated. The average primary 
irritation index was found to be 0.027. The results 
indicated that optimized formulations S1 and P1 were 
compatible with skin (Staub, Schapoval, Bergold, 2005).
FIGURE 12(a) - Mice skin for observation of erythema at 0 h.
FIGURE 12(b) - Mice skin for observation of erythema at 24 h.
FIGURE 12(c) - Mice skin for observation of erythema after 
48 h.
Stability studies
Stability studies were conducted for the optimized 
organogels for three months, and results were given 
in the Table VIII. The optimized formulations were 
evaluated for visual appearance, drug content, drug 
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TABLE VII - Results of skin irritation study
Formulation code Study sample Type
Parameter
Primary irritation indexErythema*
0 h 24 h 48 h
S1 Set 1
Control 0 0 0 P11=0/3=0
Test 0 0 0 P11=0/3=0
S1 Set 2
Control 0 0 0 P11=0/3=0
Test 0 0 0.5 P11=0.5/3=0.16
S1 Set 3
Control 0 0 0 P11=0/3=0
Test 0 0 0 P11=0/3=0
P1 Set 4
Control 0 0 0 P11=0/3=0
Test 0 0 0 P11=0/3=0
P1 Set 5
Control 0 0 0 P11=0/3=0
Test 0 0 0.5 PII=0.5/3=0.16
P1 Set 6
Control 0 0 0 P11=0/3=0
Test 0 0 0 P11=0/3=0
* Average primary irritation index = 0 +0 + 0 + 0,16 +0 + 0 + 0 + 0 + 0 + 0,16 + 0 +0,12 = 0.027
release and pH. There was no significant variation in 
visual appearance, drug release, drug content and pH 
of both span 60 based and pluronic lecithin organogels. 
The results indicated that the optimized formulations 
were found to be physically and chemically stable 
throughout the study period. This result was in 
agreement with the previous data reported by Nesseem 
(Nesseem, 2001).
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TABLE VIII - Stability studies of optimized formulations S1 and P1
Formulation code Parameters evaluated
Storage temperatures
25+2 ºC±SD 40+2 ºC±SD
S1
Visual appearance Yellowish creamy and no phase separation
Drug content* 99.46±0.002 99.98±0.012
pH* 6.90.1±0.1 7.10±0.2
% Drug release 99.4±0.001 100.01±0.002
P1
Visual appearance Yellowish creamy and no phase separation
Drug content 99.25±0.101 99.97±0.002
pH 7.1±0.1 7.1±0.1
% Drug release 69.7±0.001 71.01±0.002
(*SD=Standard Deviation)
CONCLUSION
The development of safer and more effective drug 
delivery systems of antifungal agents has radically 
changed the treatment options of fungal infections. In 
this study, different gel-based systems were developed 
for amphotericin B and evaluated for its efficacy 
to prevent fungal infections. Based on the results, 
organogels prepared by sorbitan monostearate showed 
better antifungal activity, and also all the formulations 
were found to be stable and safe throughout the study 
period. Certainly, these findings can be applied for the 
treatment of topical fungal infections.
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